[The choice of chemotherapy under PET/CT-guided treatment de-escalation has a significant impact on fertility and quality of life in young Hodgkin's lymphoma patients]
- PMID: 35459961
- DOI: 10.1007/s00066-022-01946-x
[The choice of chemotherapy under PET/CT-guided treatment de-escalation has a significant impact on fertility and quality of life in young Hodgkin's lymphoma patients]
Comment on
-
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.Lancet Oncol. 2019 Feb;20(2):202-215. doi: 10.1016/S1470-2045(18)30784-8. Epub 2019 Jan 15. Lancet Oncol. 2019. PMID: 30658935 Clinical Trial.
References
Literatur
-
- Øvlisen AK et al (2021) Parenthood rates and use of assisted reproductive techniques in younger Hodgkin lymphoma survivors: a Danish population-based study. J Clin Oncol 39:3463–3472 - DOI
-
- Gallamini A et al (2007) Early interim 2‑[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746–3752 - DOI
-
- Carde P et al (2016) Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPP baseline in stage III to IV, international prognostic score ≥ 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 intergroup trial. J Clin Oncol 34:2028–2036 - DOI
-
- Scorsetti M et al (2020) Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin’s lymphoma. Assessment of risk of toxicity and secondary cancer induction. Radiat Oncol 15:12 - DOI
-
- Casasnovas R‑O et al (2019) PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol 20:202–215 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
